Amundi Sells 14,170 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Amundi lowered its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 37.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 23,805 shares of the biotechnology company's stock after selling 14,170 shares during the period. Amundi's holdings in Exelixis were worth $821,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Tri Ri Asset Management Corp bought a new position in Exelixis during the 3rd quarter valued at about $4,396,000. Blue Trust Inc. lifted its stake in Exelixis by 134.7% during the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company's stock valued at $476,000 after acquiring an additional 8,208 shares during the period. Navellier & Associates Inc. bought a new position in Exelixis during the 3rd quarter valued at about $573,000. Intech Investment Management LLC lifted its stake in Exelixis by 48.2% during the 3rd quarter. Intech Investment Management LLC now owns 232,041 shares of the biotechnology company's stock valued at $6,021,000 after acquiring an additional 75,489 shares during the period. Finally, Range Financial Group LLC purchased a new stake in shares of Exelixis during the 4th quarter valued at about $994,000. Institutional investors own 85.27% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on EXEL. Brookline Capital Management began coverage on shares of Exelixis in a research report on Monday, December 23rd. They set a "buy" rating for the company. BMO Capital Markets lowered shares of Exelixis from an "outperform" rating to a "market perform" rating and upped their price target for the company from $36.00 to $40.00 in a research report on Friday, December 20th. UBS Group upped their price target on shares of Exelixis from $30.00 to $34.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. Stephens reaffirmed an "equal weight" rating and set a $29.00 price target on shares of Exelixis in a research report on Wednesday, February 12th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $41.00 price target on shares of Exelixis in a research report on Thursday, January 23rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $37.59.

Remove Ads

Insider Activity

In other news, Director Jack L. Wyszomierski sold 8,768 shares of the stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $37.80, for a total transaction of $331,430.40. Following the completion of the transaction, the director now directly owns 356,605 shares in the company, valued at approximately $13,479,669. This represents a 2.40 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Patrick J. Haley sold 10,000 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the completion of the sale, the executive vice president now owns 341,028 shares of the company's stock, valued at approximately $13,231,886.40. This represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is currently owned by insiders.

Exelixis Stock Down 0.6 %

EXEL stock traded down $0.22 during midday trading on Friday, hitting $36.96. The company's stock had a trading volume of 7,318,911 shares, compared to its average volume of 2,088,130. Exelixis, Inc. has a 12 month low of $20.14 and a 12 month high of $40.02. The firm has a market capitalization of $10.34 billion, a price-to-earnings ratio of 20.88, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The company has a 50 day moving average of $35.61 and a two-hundred day moving average of $32.86.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.